| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 37,228 | 225,607 | 150,864 | 101,005 |
| Cost of goods sold | 25,772 | 73,641 | 36,251 | 27,630 |
| Selling, general and administrative | 65,186 | 100,174 | 79,743 | 73,810 |
| Research and development | 15,161 | 10,286 | 13,221 | 10,395 |
| Write-down to fair value for asset held for sale | NaN | 1,940 | 922 | 1,746 |
| Total operating expenses | 106,119 | 186,041 | 130,137 | 113,581 |
| Loss from operations | -68,891 | 63,289 | 20,727 | -12,576 |
| Interest income, net | -380 | -236 | -415 | -669 |
| Other income, net | 38 | -98 | 18 | 73 |
| Total other income, net | 418 | 138 | 433 | 742 |
| Net loss before income taxes | -68,473 | 63,427 | 21,160 | -11,834 |
| Income tax benefit | -15,317 | 19,727 | -407 | -2,442 |
| Net loss and comprehensive loss | -53,156 | 43,700 | 21,567 | -9,392 |
| Accretion of redeemable convertible preferred stock to redemption value | 159 | 150 | 140 | 129 |
| Cumulative dividend on redeemable convertible preferred stock | 2,844 | 2,788 | 2,734 | 2,681 |
| Undistributed earnings allocated to participating redeemable convertible preferred stock | NaN | 1,472 | 4,168 | NaN |
| Net loss attributable to common stockholders, basic, total | -56,159 | 39,290 | 14,525 | -12,202 |
| Basic EPS | -0.44 | 0.31 | 0.11 | -0.1 |
| Diluted EPS | -0.44 | 0.287 | 0.11 | -0.1 |
| Basic Average Shares | 127,797,013 | 126,921,657 | 126,881,709 | 126,853,536 |
| Diluted Average Shares | 127,797,013 | 136,995,475 | 130,848,995 | 126,853,536 |
Organogenesis Holdings Inc. (ORGO)
Organogenesis Holdings Inc. (ORGO)